These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27246979)

  • 1. Cdc6 contributes to cisplatin-resistance by activation of ATR-Chk1 pathway in bladder cancer cells.
    Chen S; Chen X; Xie G; He Y; Yan D; Zheng D; Li S; Fu X; Li Y; Pang X; Hu Z; Li H; Tan W; Li J
    Oncotarget; 2016 Jun; 7(26):40362-40376. PubMed ID: 27246979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.
    Karanika S; Karantanos T; Li L; Wang J; Park S; Yang G; Zuo X; Song JH; Maity SN; Manyam GC; Broom B; Aparicio AM; Gallick GE; Troncoso P; Corn PG; Navone N; Zhang W; Li S; Thompson TC
    Cell Rep; 2017 Feb; 18(8):1970-1981. PubMed ID: 28228262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer.
    Li CC; Yang JC; Lu MC; Lee CL; Peng CY; Hsu WY; Dai YH; Chang FR; Zhang DY; Wu WJ; Wu YC
    Oncotarget; 2016 Jan; 7(2):1947-59. PubMed ID: 26657501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDC6 interaction with ATR regulates activation of a replication checkpoint in higher eukaryotic cells.
    Yoshida K; Sugimoto N; Iwahori S; Yugawa T; Narisawa-Saito M; Kiyono T; Fujita M
    J Cell Sci; 2010 Jan; 123(Pt 2):225-35. PubMed ID: 20048340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Norcantharidin inhibits DNA replication and induces mitotic catastrophe by degrading initiation protein Cdc6.
    Chen S; Wan P; Ding W; Li F; He C; Chen P; Li H; Hu Z; Tan W; Li J
    Int J Mol Med; 2013 Jul; 32(1):43-50. PubMed ID: 23612688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors.
    Jo U; Murai Y; Chakka S; Chen L; Cheng K; Murai J; Saha LK; Miller Jenkins LM; Pommier Y
    Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33536335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells.
    Tyagi A; Singh RP; Agarwal C; Siriwardana S; Sclafani RA; Agarwal R
    Carcinogenesis; 2005 Nov; 26(11):1978-87. PubMed ID: 15975956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights into ATR inhibition in muscle invasive bladder cancer: The role of apolipoprotein B mRNA editing catalytic subunit 3B.
    Kim H; Cho U; Hong SH; Park HS; Kim IH; An HJ; Shim BY; Kang JH
    Oncol Res; 2024; 32(6):1021-1030. PubMed ID: 38827321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
    Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
    Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irradiation-induced G2/M checkpoint response requires ERK1/2 activation.
    Yan Y; Black CP; Cowan KH
    Oncogene; 2007 Jul; 26(32):4689-98. PubMed ID: 17297454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxic activation of ATR and the suppression of the initiation of DNA replication through cdc6 degradation.
    Martin L; Rainey M; Santocanale C; Gardner LB
    Oncogene; 2012 Sep; 31(36):4076-84. PubMed ID: 22179839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression.
    Daga M; Pizzimenti S; Dianzani C; Cucci MA; Cavalli R; Grattarola M; Ferrara B; Scariot V; Trotta F; Barrera G
    Phytomedicine; 2019 Mar; 56():156-164. PubMed ID: 30668336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer.
    Meng Y; Chen CW; Yung MMH; Sun W; Sun J; Li Z; Li J; Li Z; Zhou W; Liu SS; Cheung ANY; Ngan HYS; Braisted JC; Kai Y; Peng W; Tzatsos A; Li Y; Dai Z; Zheng W; Chan DW; Zhu W
    Cancer Lett; 2018 Aug; 428():104-116. PubMed ID: 29704517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATR (AT mutated Rad3 related) activity stabilizes Cdc6 and delays G2/M-phase entry during hydroxyurea-induced S-phase arrest of HeLa cells.
    Liu L; Choi JH; Yim H; Choi JS; Park BD; Cho SJ; Lee SK
    Int J Biochem Cell Biol; 2009 Jun; 41(6):1410-20. PubMed ID: 19154794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
    Ali AY; Abedini MR; Tsang BK
    Oncogene; 2012 Apr; 31(17):2175-86. PubMed ID: 21927021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR/Chk1 targeting in medulloblastoma cells.
    Krüger K; Geist K; Stuhldreier F; Schumacher L; Blümel L; Remke M; Wesselborg S; Stork B; Klöcker N; Bormann S; Roos WP; Honnen S; Fritz G
    Cancer Lett; 2018 Aug; 430():34-46. PubMed ID: 29753759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cleavage of Cdc6 by caspase-3 promotes ATM/ATR kinase-mediated apoptosis of HeLa cells.
    Yim H; Hwang IS; Choi JS; Chun KH; Jin YH; Ham YM; Lee KY; Lee SK
    J Cell Biol; 2006 Jul; 174(1):77-88. PubMed ID: 16801388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human replication protein Cdc6 prevents mitosis through a checkpoint mechanism that implicates Chk1.
    Clay-Farrace L; Pelizon C; Santamaria D; Pines J; Laskey RA
    EMBO J; 2003 Feb; 22(3):704-12. PubMed ID: 12554670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CircUGGT2 facilitates progression and cisplatin resistance of bladder cancer through nonhomologous end-joining pathway.
    Lyu F; Huang S; Yan Z; He Q; Liu C; Cheng L; Cong Y; Chen K; Song Y; Xing Y
    Cell Signal; 2024 Jul; 119():111164. PubMed ID: 38583745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SLFN11 and ATR as targets for overcoming cisplatin resistance in ovarian cancer cells.
    König P; Eichhorn JM; Suparman E; Bückreiß N; Cinatl J; Michaelis M; Bendas G
    Biochim Biophys Acta Mol Basis Dis; 2024 Dec; 1870(8):167448. PubMed ID: 39117290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.